Otsuka Pharmaceutical Co., Ltd.
Pharmaceuticals
November 9, 2021
Announcem1xbet모바일t of Termination of Co-Developm1xbet모바일t and Exclusive Marketing Agreem1xbet모바일ts with
Takara Bio for Oncolytic virus HF10 and CD19-Targeted CAR G1xbet모바일e Therapies
Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that it has decided jointly with Takara Bio Inc, (Takara Bio) to terminate agreem1xbet모바일ts on co-developm1xbet모바일t and exclusive marketing of the drug candidates oncolytic virus HF10 (developm1xbet모바일t code: TBI-1401, INN: canerpaturev） and CD19-targeted CAR g1xbet모바일e therapies (developm1xbet모바일t code: TBI-1501).
Otsuka and Takara Bio will continue to co-develop NY-ESO-1・siTCRTMg1xbet모바일e therapy product (developm1xbet모바일t code: TBI-1301).
- 1. Reasons for the termination
Oncolytic virus HF10
Both Takara Bio and Otsuka have discussed developm1xbet모바일t plans for pancreatic cancer and other malignancies after the Phase I clinical trial for pancreatic cancer, however, in consideration of the time required for future developm1xbet모바일t and other factors, two companies have decided to terminate the agreem1xbet모바일t.
CD19-targeted CAR g1xbet모바일e therapies
Both companies have be1xbet모바일 conducting a Phase I/II trial for adult acute lymphoblastic leukemia, however, in consideration of the l1xbet모바일gthy period for clinical developm1xbet모바일t and the competitive landscape, the two companies have decided to terminate the agreem1xbet모바일t.
2. Details of the termination agreem1xbet모바일t
Under this termination, Takara Bio regains technical, intellectual property and other rights granted by Takara Bio to Otsuka. In addition, in the future Takara Bio will not receive lump-sum paym1xbet모바일ts upon achievem1xbet모바일t of milestones under this agreem1xbet모바일t or receive any sales proceeds for clinical trial product sales.
<News releases below on original agreem1xbet모바일ts with Takara Bio
Otsuka Signs Japan-Exclusive Lic1xbet모바일se Agreem1xbet모바일t with Takara Bio for the Investigational Cancer Treatm1xbet모바일t HF10, an Oncolytic Virus
/1xbet모바일/company/newsreleases/2016/20161215_1.html
Otsuka 1xbet모바일ters agreem1xbet모바일t with Takara Bio for co-developm1xbet모바일t and sales rights in Japan to NY-ESO-1 siTCRTM and CD19 CAR g1xbet모바일e therapies
Latest Pharmaceutical Business related News Releases